In vitro activity of daptomycin against multidrug-resistant Staphylococcus aureus and S. aureus with known virulence factors, including community-acquired methicillin-resistant isolates.
The in vitro activity of daptomycin was evaluated against 360 multidrug-resistant Staphylococcus aureus isolates (including hospital-acquired isolates) and multidrug-susceptible community-acquired methicillin-resistant S. aureus with known virulence genes. All isolates were inhibited at <or=1 microg/mL, suggesting that daptomycin has excellent activity against both hospital-acquired and community-acquired S. aureus isolates.
Anastasiou
Diane M
DM
Cubist Pharmaceuticals Inc., Lexington, MA 02421, USA. diane.anastasiou@cubist.com
Morgan
Margie
M
Ruane
Peter J
PJ
Steenbergen
Judith N
JN
Katz
Bradley D
BD
Alder
Jeff D
JD
Thorne
Grace M
GM
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017714:Community-Acquired Infections / Q000382:microbiology; D003428:Cross Infection / Q000382:microbiology; D017576:Daptomycin / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D013203:Staphylococcal Infections / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D037521:Virulence Factors / Q000032:analysis*
D000900:Anti-Bacterial Agents; D037521:Virulence Factors; D017576:Daptomycin